The CRISPR Revolution and the New Era of Genome Editing



Kevin Davies PhD

Executive Editor, *The CRISPR Journal;*

Author, *Editing Humanity*

SCOS/NCOA 2024

Charlotte NC | 2.17.24



AI in Precision Oncology
Volume 1, Number 1X, 2023

DOI: 10.1089/aipo.2023.28999.editorial

AI IN PRECISION ONCOLOGY

Open camera or QR reader and scan code to access this article and other resources online.

EDITORIAL

Introducing *AI in Precision Oncology*

Douglas B. Flora*

Welcome to *AI in Precision Oncology*, a pioneering peer-reviewed research journal rooted in the transformative power of artificial intelligence (AI) in oncology. This journal will serve as a robust platform for disseminating rigorous, groundbreaking, high-quality peer-reviewed research, review articles, and captivating frontmatter to support the interests, needs, and innovation in the field and industry.

My foremost goal as editor-in-chief, along with the goals of the incredible team of editorial board members, is to inform, innovate, and inspire. With this journal serving as a main resource in the field, we will support clinicians, researchers, AI experts, patients, and industry leaders with up-to-date advancements in the field while fostering an environment conducive to further innovation and collaboration. The genesis of the journal is fundamentally linked to my personal commitment to improving cancer care across the field by supporting AI-enabled health care systems that are accessible, efficient, and, most importantly, effective for everyone.

Along with this, *AI in Precision Oncology* will serve as a catalyst between worlds. The fusion of both AI-enabled technologies and precision oncology is advancing at an unprecedented pace; however, a divide currently exists between these technological strides and their pragmatic integration into clinical settings. Clinicians, rightly so, require a trove of evidence-based research to acquaint themselves with AI tools and understand the methodologies to incorporate them into their practice. With this journal serving as a foremost resource, and the exceptional research-based content we will provide to the community, we aspire to bridge this divide.

Furthermore, *AI in Precision Oncology* will serve as an educational compass for health care professionals who might be unacquainted with AI. The journal will provide review articles, commentaries, tutorials, tools, protocols, and thought-leader profiles to inform health care professionals and allow a better understanding of the available tools and how to implement them and integrate them into their own clinical practices. AI can afford health care providers the luxury of time by automating time-consuming tasks that do not necessitate a human touch, such as data analysis or administrative chores.

Clinicians can then direct their time toward engaging more meaningfully with patients, improving patient satisfaction, and enhancing the quality of care by enabling more comprehensive and personalized consultations.

Our goal is to bring together researchers, clinicians, and industry experts to share their knowledge and experience in this rapidly evolving field. We warmly welcome a variety of article formats including original research articles, reviews, and perspectives on applying AI in cancer research, diagnosis, and treatment. Some of our key areas of interest include (but are not limited to):

- AI algorithms for cancer detection, diagnosis, and prognosis
- AI-based biomarkers for cancer screening and diagnosis
- AI-assisted imaging analysis for tumor detection and segmentation
- AI-guided treatment planning and personalized therapy
- AI-enabled drug discovery and development
- Machine learning and deep learning in cancer research
- Natural language processing for electronic health record analysis
- Ethical and regulatory issues in AI in precision oncology

Editor-in-Chief, *AI in Precision Oncology*

“My Dear Michael…

19 March 1953


In other words if we think we have found the basic copying mechanism by which life come from life. The beauty of our model is that the shape of it is such that only these pairs can go together, though they could pair up in other ways if they were floating about freely. You can understand that we are very excited. We have to have a letter at to Nature in a day or so.

Read this carefully so that you understand it. Later you come home we will show you the model.

Lots of love,

Daddy

“Jim Watson and I have probably made a most important discovery…

Our structure is very beautiful. D.N.A. can be thought of roughly as a very long chain with flat bits sticking out. The flat bits are called the ‘bases’…”

Photograph 51



Sir Shankar Balasubramanian Sir David Klenerman

Cost of a Single Human Genome



THE FASTEST DNA SEQUENCING >>> TECHNIQUE

Who
EUAN ASHLEY, ULTRA-RAPID GENOME TEAM

What
05:02:00
HOUR(S):MINUTE(S):SECOND(S)

Where
UNITED STATES (STANFORD)

When
16 MARCH 2021

CRISPR


TIME
The Gene Machine
What the CRISPR experiments mean for humanity By Alice Park


The Economist
How Russians cope with recession
No-go for NGOs in China
Islamic State's taste for slavery
Commodities: the binge, the hangover
India's poet-politicians
Editing humanity
The prospect of genetic enhancement
High IQ
No baldness
Low risk of Alzheimer's, breast cancer and strokes
Perfect pitch
Sprinter
20/20 vision
A
T
G
C


'Panda Babies: Mission Critical'
August 28 at 8/7c on the Nat Geo WILD channel
AUGUST 2016
NATIONAL GEOGRAPHIC
The DNA REVOLUTION
With new gene-editing techniques, we can transform life—but should we?


No hunger.
No pollution.
No disease.
WIRED
And the end of life as we know it.
The Genesis Engine.


C&EN
CHEMICAL & ENGINEERING NEWS
SEPTEMBER 7, 2015
DISRUPTING PRIONS
Small molecules target progressive diseases P.37
BOSTON IN PHOTOS
Sights from the fall 2015 ACS national meeting P.48
EDITING THE GENOME
CRISPR/Cas9 takes gene manipulation into a new era P.14
PUBLISHED BY THE AMERICAN CHEMICAL SOCIETY


The risks of using CRISPR to edit embryos
ENERGYGUIDE
VWR
60 MINUTES Overtime
April 2018

In 1993, a breakthrough new technology, known as CRISPR, gave scientists a path to treat incurable diseases through genetic editing.

In 2016, due to its potential for misuse, the U.S. Intelligence Community designated genetic editing a ‘Weapon of Mass Destruction and Proliferation.’

“Are you familiar with CRISPR?”


Jeopardy! November 29, 2019
JENNIFER DOUDNA &
EMMANUELLE
CHARPENTIER
ARE CO-INVENTORS OF
THE REVOLUTIONARY
TOOL CRISPR TO EDIT
THESE IN THE BODY

The Nobel Prize in Chemistry 2020

awarded jointly to

Emmanuelle Charpentier

&

Jennifer A. Doudna

"for the development of a method for genome editing."

October 7, 2020

Francisco Mojica PhD
(University of Alicante)
Salterns of Santa Pola, Spain

An “unusual arrangement” in *E. coli* (1987)



Ishino Y. *et al*. *J. Bacteriol*. 2018



Asunto: **Re: Acronym**
Fecha: Wed, 21 Nov 2001 16:39:06 +0100
De: "Ruud Jansen" <R.Jansen@vet.uu.nl>
Empresa: Diergeneeskunde
A: "Francisco J. Martínez Mojica" <fmojica@ua.es>

Dear Francis

What a great acronym is CRISPR.
I feel that every letter that was removed in the alternatives made it less crispy so I prefer the snappy CRISPR over SRSR and SPIDR.
Also not unimportant is the fact that in MedLine CRISPR is a unique entry, which is not true for some of the other shorter acronyms.

JOURNAL OF MOLECULAR EVOLUTION

Intervening Sequences of Regularly Spaced Prokaryotic Repeats Derive from Foreign Genetic Elements

Francisco J.M. Mojica, César Díez-Villaseñor, Jesús García-Martínez, Elena Soria

División de Microbiología, Departamento de Fisiología, Genética y Microbiología, Universidad de Alicante, Campus de San Vicente, E-03080, Spain

Received: 6 February 2004 / Accepted: 1 October 2004 [*Reviewing Editor:* Dr. John Huelsenbeck]



ARTICLES

Highly efficient endogenous human gene correction using designed zinc-finger nucleases

Fyodor D. Urnov[1], Jeffrey C. Miller[1], Ya-Li Lee[1], Christian M. Beausejour[1], Jeremy M. Rock[1], Sheldon Augustus[1], Andrew C. Jamieson[1], Matthew H. Porteus[2], Philip D. Gregory[1] & Michael C. Holmes[1]

Permanent modification of the human genome *in vivo* is impractical owing to the low frequency of homologous recombination in human cells, a fact that hampers biomedical research and progress towards safe and effective gene therapy. Here we report a general solution using two fundamental biological processes: DNA recognition by C_2H_2 zinc-finger proteins and homology-directed repair of DNA double-strand breaks. Zinc-finger proteins engineered to recognize a unique chromosomal site can be fused to a nuclease domain, and a double-strand break induced by the resulting zinc-finger nuclease can create specific sequence alterations by stimulating homologous recombination between the chromosome and an extrachromosomal DNA donor. We show that zinc-finger nucleases designed against an X-linked severe combined immune deficiency (SCID) mutation in the *IL2R*γ gene yielded more than 18% gene-modified human cells without selection. Remarkably, about 7% of the cells acquired the desired genetic modification on both X chromosomes, with cell genotype accurately reflected at the messenger RNA and protein levels. We observe comparably high frequencies in human T cells, raising the possibility of strategies based on zinc-finger nucleases for the treatment of disease.

Courtesy:
HUMAN NATURE

Fyodor Urnov
Innovative Genomics Institute

Rodolphe Barrangou
NC State
EIC, *CRISPR Journal*

CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes

Rodolphe Barrangou,[1] Christophe Fremaux,[2] Hélène Deveau,[3] Melissa Richards,[1] Patrick Boyaval,[2] Sylvain Moineau,[3] Dennis A. Romero,[1] Philippe Horvath[2]*

Science 2007

CRISPR

… is a natural bacterial immune defense system that provides a means to recognize, remember and destroy viral invaders.



Bhaya *et al. Ann Rev Genet* 2011

Team Doudna/Charpentier



Stanley Hall
UC Berkeley, 2012

A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity

Martin Jinek,[1,2*] Krzysztof Chylinski,[3,4*] Ines Fonfara,[4] Michael Hauer,[2†]
Jennifer A. Doudna,[1,2,5,6‡] Emmanuelle Charpentier[4‡]

Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) syst
provide bacteria and archaea with adaptive immunity against viruses and plasmids by using
CRISPR RNAs (crRNAs) to guide the silencing of invading nucleic acids. We show here that in

Lights. Camera. Action… **CUT!**

CRISPR-Cas9 visualized by high-speed atomic force microscopy



M. Shibata, H. Nishimasu *et al*.
Nature Communications 8, 1430 (2017)

Hiroshi Nishimasu (Univ Tokyo)

The “Genetic Scissors”



Cas9 nuclease

Dominguez et al.
Nat Rev Mol Cel Biol. 2015

PUBLIC

PRIVATE

HEALTH AND SCIENCE

U.S. approves first gene-editing treatment, Casgevy, for sickle cell disease

PUBLISHED FRI, DEC 8 2023•11:19 AM EST | UPDATED FRI, DEC 8

Angelica Peebles
@IN/ANGELICAPEEBLES/
@ANGELICAPEEBLES

Annika Kim Constantino
@ANNIKAKIMC

F.D.A. Approves Sickle Cell Treatments, Including One That Uses CRISPR

People with the genetic disease have new opportunities to eliminate their symptoms, but the treatments come with obstacles that limit their reach.

The world's first CRISPR therapy is approved: who will receive it?

The go-ahead for Vertex's gene editing therapy in sickle cell disease and β-thalassemia is a historic milestone, but this one-time treatment is costly.

December 8, 2023

Sickle Cell Anemia: The First Molecular Disease



Dr James Herrick
Rush Presbyterian Hospital, Chicago



Figure 1. These photomicrographs show the peculiar elongated forms of the red corpuscles. Occasional shadow forms are seen with a few nucleated reds. The variations in shape and size are best made out in the low-power figure. The relatively number of white corpuscles and of normoblasts is not shown by these particular figures.

Meredith Rizzo / NPR

Victoria Gray

Forest, Mississippi

First patient to receive CRISPR gene therapy for sickle-cell disease in the USA

- 46% total HbF
- 99.7% red blood cells contain some HbF.

ORIGINAL ARTICLE BRIEF REPORT

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia

Haydar Frangoul, M.D., David Altshuler, M.D., Ph.D., M. Domenica Cappellini, M.D., Yi-Shan Chen, Ph.D., Jennifer Domm, M.D., Brenda K. Eustace, Ph.D., Juergen Foell, M.D., Josu de la Fuente, M.D., Ph.D., Stephan Grupp, M.D., Ph.D., Rupert Handgretinger, M.D., Tony W. Ho, M.D., Antonis Kattamis, M.D., Andrew Kernytsky, Ph.D., Julie Lekstrom-Himes, M.D., Amanda M. Li, M.D., Franco Locatelli, M.D., Markus Y. Mapara, M.D., Ph.D., Mariane de Montalembert, M.D., Damiano Rondelli, M.D., Akshay Sharma, M.B., B.S., Sujit Sheth, M.D., Sandeep Soni, M.D., Martin H. Steinberg, M.D., Donna Wall, M.D., Angela Yen, Ph.D., and Selim Corbacioglu, M.D.

CRISPR Tx + Vertex | July 2019



"I remember waking up without any pain and feeling lost, because my life is so associated with pain.
It's just a part of who I am.
It's weird now that I don't experience it anymore."

– Jimi Olaghere

Jimi Olaghere/BBC 2.19.22

Before and After: VOCs in Patients Receiving Exa-cel Therapy

(Studies 121 and 131)



Vertex Pharmaceuticals (October 2023)

In vivo Genome Editing

ORIGINAL ARTICLE

CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis

Julian D. Gillmore, M.D., Ph.D., Ed Gane, M.B., Ch.B., Jorg Taubel, M.D., Justin Kao, M.B., Ch.B., Marianna Fontana, M.D., Ph.D., Michael L. Maitland, M.D., Ph.D., Jessica Seitzer, B.S., Daniel O'Connell, Ph.D., Kathryn R. Walsh, Ph.D., Kristy Wood, Ph.D., Jonathan Phillips, Ph.D., Yuanxin Xu, M.D., Ph.D., Adam Amaral, B.A., Adam P. Boyd, Ph.D., Jeffrey E. Cehelsky, M.B.A., Mark D. McKee, M.D., Andrew Schiermeier, Ph.D., Olivier Harari, M.B., B.Chir., Ph.D., Andrew Murphy, Ph.D., Christos A. Kyratsous, Ph.D., Brian Zambrowicz, Ph.D., Randy Soltys, Ph.D., David E. Gutstein, M.D., John Leonard, M.D., Laura Sepp-Lorenzino, Ph.D., and David Lebwohl, M.D.



NEJM June 2021

NEW ZEALAND / SCIENCE

Ground-breaking gene-editing treatment leaves patient feeling like they have 'a new body'

12:49 pm on 25 January 2023

Share this

Niva Chittock, Reporter
niva.chittock@rnz.co.nz

Being given a whole new body might sound like something from a sci-fi movie but a New Zealander [Judy Knox] says a new genetic treatment has felt just like that.

Hereditary angioedema is a rare immune deficiency that causes random, disabling and potentially lethal swelling…

Intellia Therapeutics chose New Zealand to be the first place to trial a ground-breaking gene-editing technology in late 2021 and 2022…

"… Adoptive transfer of engineered T cells into patients resulted in durable engraftment with edits at all three genomic loci… Modified T cells persisted for up to 9 months, suggesting that immunogenicity is minimal under these conditions and **demonstrating the feasibility of CRISPR gene editing for cancer immunotherapy**."





NCI

World-first use of base-edited cells to treat ‘incurable’ leukaemia

Alyssa

T-acute lymphoblastic leukemia

Bone Marrow Transplant Unit,
Great Ormond Street Hospital,
London

Diagnosed May 2021
Treated May 2022

Prof. Waseem Qasim

12 December 2022


David Liu
Broad Institute/HHMI

Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage

Alexis C. Komor[1,2], Yongjoo B. Kim[1,2], Michael S. Packer[1,2], John A. Zuris[1,2] & David R. Liu[1,2]



Alexis Komor
(UCSD)

Programmable base editing of A·T to G·C in genomic DNA without DNA cleavage

Nicole Gaudelli
(Beam Therapeutics)

Nicole M. Gaudelli[1,2,3], Alexis C. Komor[1,2,3]†, Holly A. Rees[1,2,3], Michael S. Packer[1,2,3]†, Ahmed H. Badran[1,2,3], David I. Bryson[1,2,3]† & David R. Liu[1,2,3]

MEGAN MOLTENI SCIENCE 10.21.2019 11:00 AM

A New Crispr Technique Could Fix Almost All Genetic Diseases

A less error-prone DNA editing method could correct many more harmful mutations than was previously possible.

RESEARCH HIGHLIGHT | 16 February 2023

Genome editor tackles disease that can cause sudden death

Scientists repair a mutation that causes heart-muscle abnormalities and can kill without warning.

Beam Therapeutics Cofounder And Crispr Scientist Publishes Research On New Sickle Cell Treatment In Mice

Leah Rosenbaum Forbes Staff
Innovation
I write about the business of healthcare.

David Liu inside his office at the Broad Institute in Cambridge, MA. BOSTON GLOBE VIA

Science Contents News Careers Jou

SHARE

12K

A 4-year-old with progeria, a syndrome with features of premature aging that stems from a mutated gene MARTIN ZABALA XINHUA/EYEVIN/REDUX

‘Incredible’ gene-editing result in mice inspires plans to treat premature-aging syndrome in children

By Jocelyn Kaiser | Jan. 6, 2021 , 11:00 AM

One-time CRISPR hit lowers cholesterol in monkeys

Verve Therapeutics demonstrates long-term LDL reduction for base editor therapy

*by **Alla Katsnelson, special to C&EN***

May 19, 2021 | A version of this story appeared in **Volume 99, Issue 19**

1

High blood LDL-C leads to clogged arteries in the heart resulting in ASCVD.



3

Turning off the *PCSK9* gene results in lower blood LDL-C lifelong, and thus treats ASCVD.

2a

We deliver our drug, VERVE-101, via intravenous infusion into the blood.

VERVE-101 gets taken up into the liver. The gRNA and mRNA are ultimately released inside the liver cells, into the cytoplasm.

2b

The mRNA is translated into the base editing protein ABE which binds to the gRNA and together travel to the nucleus. Within the nucleus, this complex scans the DNA using the gRNA to find the target gene *PCSK9* and makes a specific A-to-G spelling change within the gene.

2c

A single spelling change in the DNA sequence permanently turns off the *PCSK9* gene.

verve THERAPEUTICS

Base editing *PCSK9*: A potential "one and done" cure for heart disease?

CRISPR in the Clinic

Sponsor	Program	Disease	# patients	Notes
CRISPR Tx	exa-cel	Sickle cell/beta-thal	75	+ Vertex
	CTX110	CAR-T/B-cell malignancies	32	
	CTX130	CAR-T/solid tumors + blood	18	
	VCTX210	Type 1 diabetes	10	+ Viacyte
INTELLIA	2001	Transthyretin amyloidosis	27	+ Regeneron
	2002	Hereditary angiodema	10	
	5001	TCR-T-cell/AML	1+	
	OTQ923	Sickle cell	2+	
EDITAS	101	Leber congenital amaurosis 10	14	
	301	Sickle cell	2	
VERVE Tx	101	Familial hypercholesterolemia	4	+ Eli Lilly
CARIBOU	CB-010	CAR-T/non-Hodgkin lymphoma	9	
	CB-011	CAR-T/multiple myeloma	coming	
BEAM Tx	101	Sickle-cell	1+	*base editing*
	201	CAR-T/T-ALL	2+	
GRAPHITE BIO	nula-cel	Sickle-cell	1	*Abandoned

More than 200 patients have or are currently receiving CRISPR genome editing in clinical trials (Mar 2023)

“The invention of CRISPR gene editing gave us remarkable treatment powers, yet no one should do a victory lap. Scientists can rewrite a person’s DNA on demand. But now what? Unless things change dramatically, the millions of people CRISPR could save will never benefit from it. We must, and we can, build a world with CRISPR for all.”

Fyodor Urnov
New York Times
January 2023

Gene therapy can transform life for people with hemophilia. But some patients don't want it.

By Jonathan Saltzman Globe Staff, Updated January 29, 2023, 4:36 p.m.

Bobby Wiseman, 51, in the living room of his Rancho Cordova, Calif. home. JAKUB MOSUR/JAKUB MOSUR PHOTOGRAPHY

nature

PHARMACEUTICALS

$3.5-Million Hemophilia Gene Therapy Is World's Most Expensive Drug

A hemophilia drug has the potential to save lives. But it cannot treat the most common form of the disease


YOU WERE SO PREOCCUPIED WITH WHETHER OR NOT YOU COULD
JURASSIC PARK
YOU DIDN'T STOP TO THINK IF YOU SHOULD

Heterogeneous Diversity of Spacers within CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)
-- Jiankui He & Michael W. Deem *Phys. Rev. Lett.* **105**, 128102 (Sept 2010)

“The Baby is Born”

Hi Stephen,

Great news! the baby is born (please keep it in confidential). I am coming to San Francisco this week, will you be available for a meeting? I can come to Stanford in Wednesday, Thursday or Friday. I want to get help from you on how to announce the result, PR and ethics.

Regards,
JK

Jiankui He
Associate Professor
Southern University of Science and Technology (SUSTech)
Lab website: www.sustc-genome.org.cn
贺建奎
南方科技大学生物系副教授

Stephen Quake
Stanford/CZI

New York Times
April 14, 2019

Antonio Regalado

MIT Technology Review


PAM
Embryo 1
(Lulu)
+1 bp / - 4 bp
Embryo 2
(Nana)
-15 bp / WT
SECOND INTERNATIONAL SUMMIT ON
HUMAN GENOME EDITING
Convened by
The Academy of Sciences of Hong Kong 香港科學院
THE ROYAL SOCIETY
NATIONAL ACADEMY OF SCIENCES
NATIONAL ACADEMY OF MEDICINE

15 Reasons Why

SCIENCE

The CRISPR Baby Scandal Gets Worse by the Day

The alleged creation of the world's first gene-edited infants was full of technical errors and ethical blunders. Here are the 15 most damning details.

ED YONG DEC 3, 2018

7. A few people knew about He's intentions but failed to stop him.
8. He acted in contravention of global consensus.
9. He acted in contravention of his own stated ethical views.
10. He sought ethical advice and ignored it.
11. There is no way to tell whether He's work did any good.
12. He has doubled down.
13. Scientific academies have prevaricated.
14. A leading geneticist came to He's defense.
15. This could easily happen again.

Ed Yong, *The Atlantic*
Dec 3 2018


“ How could Dr. He and [his] team change the gene pool of the human species without considering the need to consult other parts of the human species?”
-- Qiu Renzong

Denis Rebrikov MD
Pirogov Medical University
Moscow

«Вчера было рано, завтра будет поздно. Власть надо брать сегодня».

“Yesterday was early, tomorrow will be late.
Power must be taken today.”

-- LENIN

Andrey Rudakov /
Bloomberg

Who Wants a CRISPR Clinic?

From: "xxxxxxxx"<xxxxxxx>;
Date: Wed, Dec 5, 2018 01:18 PM
To: "hejk"<xxxxxxxxx >;
Cc: "xxxxxxxx xxxx"< >;
Subject: CRISPR Gene Editing Embryology Lab Application Course

Dear He Jiankui,
Congratulations on your recent achievement of the first gene editing baby delivered by your application!
My name is XXXXXXX, and I am the Business Director's Assistant at XXXXXXXX Fertility & Gynaecology Center, in Dubai.
Our Embryologist is interested in partaking in a course regarding CRISPR gene editing for Embryology Lab Application.
Does your facility offer this type of course?

Kind regards,
XXXXXXXXXXX
Business Director's Assistant
XXXXXX

Credit: William Hurlbut



Wang & Doudna
Science 20 Jan 2023

REPORT

Inactivation of porcine endogenous retrovirus in pigs using CRISPR-Cas9

Dong Niu[1,2,*], Hong-Jiang Wei[3,4,*], Lin Lin[5,*], Haydy George[1,*], Tao Wang[1,*], I-Hsiu Lee[1,*], Hong-Ye Zhao[3], Yong Wang[6], Yinan Kan[1], Ellen Shrock[7], Emal Lesha[1], Gang Wang[1], Yonglun Luo[5], Yubo Qing[3,4], Deling Jiao[3,4], Heng Zhao[3,4], Xiaoyang Zhou[6], Shouqi Wang[8], Hong Wei[6], Marc Güell[1,†], George M. Church[1,7,9,†], Luhan Yang[1,†,‡]

[1]eGenesis, Inc., Cambridge, MA 02139, USA.

Tomato is first CRISPR-edited food to go on sale in the world

ENVIRONMENT 24 September 2021

By Michael Le Page

Tomatoes with genes edited by CRISPR technology are now on sale in Japan
Courtesy of Sanatech Seed

For the first time ever, you can now buy a food altered by CRISPR gene editing – at least, if you live in Japan, where the Sicilian Rouge High GABA tomato has just gone on sale.

"We started shipping the tomatoes on September 17," says Minako Sumiyoshi at Japanese start-up Sanatech Seed, which is selling the tomatoes directly to consumers. She says demand for the tomatoes is "not too bad".

"It is a very significant milestone for CRISPR foods," says ...

The first CRISPR gene-edited food is now on sale in Japan:
A tomato packed with an alleged increase in nutritional content.

The **Sicilian Rouge High GABA** tomato, created by Sanatech Seed, sold gene-edited seedlings to farmers in 2021 -- some 4,200 farmers took up the offer. Now, the tomatoes are ripe for sale.

sanatechseed®
For Tomorrow's Children and Earth

The UCSD Insectary

Omar Akbari

GENE DRIVES



De-Extinction: Pleistocene Park?

Eriona Hysolli
Medium December 2018

Brackett N. et al.
CRISPR Journal (April 2022).

Royal Society

THE AUTHOR OF *CRACKING THE GENOME* UNRAVELS ONE OF THE MOST IMPORTANT BREAKTHROUGHS IN MODERN SCIENCE AND MEDICINE.



"With great reporting and deep knowledge, science journalist Kevin Davies takes us to all the frontlines of CRISPR research, from gene editing to improved agriculture. It's the scientific revolution of our era, and Davies gives us a close-up view of all the important players and exciting discoveries."

—**WALTER ISAACSON,**
author of *Steve Jobs* and *The Innovators*

Davies dissects the implications CRISPR will have on our everyday lives and the lives of generations to come.

E: davieskev@gmail.com
T: @KevinADavies

John Simon Guggenheim Memorial Foundation

Mary Ann Liebert, Inc.